ArticleInternational journal of molecular sciences2021
Nanostructured Non-Ionic Surfactant Carrier-Based Gel for Topical Delivery of Desoximetasone.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Novasomal Gel for Enhanced Dermal Delivery and Antibacterial Efficacy of Cinnamic Acid.Molecules (Basel, Switzerland) · 2026Article
- The Influence of Phyto-Active Incorporated Topical Formulations on Cell Migration in Scratch Assays andCurrent drug delivery · 2026Article
- Nano-Formulated Apelin13 Reduces Cerebral Ischemia/Reperfusion Injury in Rats by Suppressing Activity of TLR4/MyD88/NF-кB Axis and Pro-inflammatory Cytokines; an Experimental Study.Archives of academic emergency medicine · 2026Article
- Review
- Antibacterial and antibiofilm activities of zingerone and niosomal zingerone against methicillin-resistantIranian journal of microbiology · 2024Article
- Crisaborole-Enthused Glycerosomal Gel for an Augmented Skin Permeation.Recent advances in drug delivery and formulation · 2024Article
- Recent Advancements and Trends of Topical Drug Delivery Systems in Psoriasis: A Review and Bibliometric Analysis.International journal of nanomedicine · 2024Review
- Development and evaluation of berberine-loaded bigel for the treatment of hyperpigmentation on B16F10 melanoma cell line.Nanomedicine (London, England) · 2024Article
- A Comparative Evaluation of Desoximetasone Cream and Ointment Formulations Using Experiments and In Silico Modeling.International journal of molecular sciences · 2023Article
- Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System.Pharmaceutics · 2023Review
- Qbd-Based Approach to Optimize Niosomal Gel of Levosulpiride for Transdermal Drug Delivery.Gels (Basel, Switzerland) · 2023Article
- Quality by Design Guided Development of Polymeric Nanospheres of Terbinafine Hydrochloride for Topical Treatment of Onychomycosis Using a Nano-Gel Formulation.Pharmaceutics · 2022Article
- Dextrin-Based Nanohydrogels for Rokitamycin Prolonged Topical Delivery.Gels (Basel, Switzerland) · 2022Article
- Gemini and Bicephalous Surfactants: A Review on Their Synthesis, Micelle Formation, and Uses.International journal of molecular sciences · 2022Review
- Synopsis of Barrier Function of Skin and Oral Mucosa-Volume 1.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic autoimmune skin disease impacting the population globally. Pharmaceutical products developed to combat this condition commonly used in clinical settings are IV bolus or oral drug delivery routes. There are some major challenges for effectively developing new dosage forms for topical use: API physicochemical nature, the severity of the disease state, and low bioavailability present challenges for pharmaceutical product developers. For non-severe cases of psoriasis, topical drug delivery systems may be preferred or used in conjunction with oral or parenteral therapy to address local symptoms. Elastic vesicular systems, termed "niosomes", are promising drug delivery vehicles developed to achieve improved drug delivery into biological membranes. This study aimed to effectively incorporate a corticosteroid into the niosomes for improving the drug bioavailability of desoximetasone, used to treat skin conditions via topical delivery. Niosomes characterization measurements were drug content, pH, spreadability, specific gravity, content uniformity, rheology, and physicochemical properties. Formulations used a topical gelling agent, Carbomer 980 to test for in vitro skin permeation testing (IVPT) and accelerated stability studies. The developed niosomal test gel provided approximately 93.03 ± 0.23% to 101.84 ± 0.11% drug content with yield stresses ranging from 16.12 to 225.54 Pa. The permeated amount of desoximetasone from the niosomal gel after 24 h was 9.75 ± 0.44 µg/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.